12 Best Penny Stocks to Invest In According to Billionaires
The article cites CNBC and discusses small-cap outperformance, attributing it to AI-related capex “trickle-down” effects and portfolio broadening. It then lists 12 penny stocks under $5, using Finviz and Insider Monkey data. It highlights Prospect Capital (PSEC) investing in ShipOffers and Iovance (IOVA) updating TIL therapy progress, including cash of ~$319M and revenue guidance of $350M–$370M.
How this was made
The 30-second read
Why it matters
Trading relevance comes only from two company-specific updates: PSEC’s ShipOffers investment announcement and IOVA’s June 30 corporate presentation with cash and revenue guidance. The rest is market narrative and methodology.
Market read
Actionable items are dated (June 30/July 6) and embedded in a promotional list; still, IOVA’s explicit guidance and cash runway are the most decision-relevant datapoints.
What to watch
For PSEC, the article omits key deal size/terms and credit risk details; for IOVA, it provides guidance but not trial readouts or regulatory milestones that could swing expectations.
Background
The article argues small-caps are benefiting from AI-related capex “trickle-down” and portfolio broadening, then presents a list of penny stocks held by billionaire investors.
Ticker impact
Prospect Capital says July 6 it invested in ShipOffers via a first-lien senior secured term loan plus an equity-linked investment.
Likely modest positive bias as investors parse incremental deployment and risk/return mix.
The article provides a specific, attributable investment announcement (deal structure and growth-capital framing), but no deal size or financial terms are given to gauge magnitude.
Iovance updated its corporate presentation June 30, citing 1,500+ patients treated, 90+ centers, $319M cash, and revenue guidance $350M-$370M.
Potentially positive near-term reaction if investors view the runway and guidance as de-risking execution.
The text includes concrete, decision-relevant datapoints (cash balance and full-year/Q2 revenue guidance) tied to a specific product trajectory (Amtagvi) and pipeline expansion.
Market effects
Supports a small-cap/AI capex read-through narrative, but provides no new sector policy or data beyond general framing.
None specific; discussion is US index performance and CNBC commentary.
ShipOffers investment mentions Netherlands facilities, but no cross-border regulatory or macro catalyst is disclosed.
Counterpoint
Because this is a “best penny stocks” listicle, the incremental trading signal may be limited versus the underlying primary disclosures (deal terms, full financial impact, and trial outcomes).
Key entities
- companyProspect Capital Corporation
BDC that announced an investment in ShipOffers via term loan plus equity-linked structure.
- companyIovance Biotherapeutics, Inc.
TIL-therapy biopharma that updated its corporate presentation with treated-patient metrics, cash, and revenue guidance.
- companyShipOffers
E-commerce fulfillment company referenced as the recipient of PSEC’s investment.
- productAmtagvi
Iovance’s lead advanced melanoma TIL therapy referenced as on a strong trajectory.
